Selective serotonin reuptake inhibitors and pulmonary arterial hypertension: A case-control study

Chest

Volumn 141, Issue 2, 2012, Pages 348-353

  Dhalla, Irfan A ^a,b,c,d,e   Juurlink, David N ^a,b,e   Gomes, Tara ^b,e   Granton, John T ^a,e   Zheng, Hong ^e   Mamdani, Muhammad M ^b,d,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BOSENTAN; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; PROSTACYCLIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SILDENAFIL; UNIPROST;

ADULT; AGED; ARTICLE; CANADA; CASE CONTROL STUDY; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; PULMONARY HYPERTENSION;

EID: 84856731450     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-0426     Document Type: Article

References (21)

1. Simonneau G, Galiè N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43(12 suppl S):5S-12S. (Pubitemid 38759712)
2. Speich R, Jenni R, Opravil M, Pfab M, Russi EW. Pri mary pulmonary hypertension in HIV infection. Chest. 1991;100(5):1268-1271.
3. Battle RW, Davitt MA, Cooper SM, et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest. 1996;110(6):1515-1519. (Pubitemid 26425153)
4. Abenhaim L, Moride Y, Brenot F, et al International Primary Pulmonary Hypertension Study Group. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med. 1996;335(9):609-616. (Pubitemid 26277950)
5. Fitzgerald LW, Burn TC, Brown BS, et al. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfl uramine. Mol Pharmacol. 2000;57(1):75-81. (Pubitemid 30033262)
6. Marcos E, Fadel E, Sanchez O, et al. Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res. 2004;94(9):1263-1270. (Pubitemid 38656414)
7. Eddahibi S, Humbert M, Fadel E, et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension . J Clin Invest. 2001;108(8):1141-1150. (Pubitemid 32995372)
8. Guignabert C, Raffestin B, Benferhat R, et al. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation. 2005;111(21):2812-2819. (Pubitemid 40791554)
9. Shah SJ, Gomberg-Maitland M, Thenappan T, Rich S. Selective serotonin reuptake inhibitors and the incidence and outcome of pulmonary hypertension. Chest. 2009;136(3):694-700.
10. Kawut SM, Horn EM, Berekashvili KK, et al. Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension. Pulm Pharmacol Ther. 2006;19(5):370-374. (Pubitemid 44051959)
11. National Institutes of Health Clinical Center. Serotonin Transporter Inhibitor Escitalopram in Pulmonary Hyper tension. NCT00190333. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2005. http://clinicaltrials.gov/ct2/show/ NCT00190333. Updated February 17, 2011.
12. National Institutes of Health Clinical Center. Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension. NCT00942708. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2009. http://clinicaltrials.gov/ ct2/show/ NCT00942708. Updated March 15, 2011.
13. Ontario Ministry of Health and Long-Term Care. Publicly funded drug programs. Ontario Ministry of Health and Long- Term Care. http://www.health.gov. on.ca/en/public/programs/ drugs/funded-drug/. Accessed August 26, 2010.
14. Dhalla IA, Mamdani MM, Sivilotti ML, Kopp A, Qureshi O, Juurlink DN. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ. 2009;181(12):891-896.
15. Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM. Trimethoprim-sulfamethoxazole-induced hyper kalemia in patients receiving inhibitors of the reninangiotensin system: a population-based study. Arch Intern Med.2010;170(12):1045-1049.
16. Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ. 2009;339:b2942.
17. Dhalla IA, Mamdani MM, Simor AE, Kopp A, Rochon PA, Juurlink DN. Are broad-spectrum fl uoroquinolones more likely to cause Clostridium difficile-associated disease? Antimicrob Agents Chemother. 2006;50(9):3216-3219. (Pubitemid 44396444)
18. Löwe B, Gräfe K, Ufer C, et al. Anxiety and depression in patients with pulmonary hypertension. Psychosom Med.2004;66(6):831-836. (Pubitemid 39552865)
19. McCollister DH, Beutz M, McLaughlin V, Rumsfeld J, Masoudi FA, Tripputi M, et al. Depressive symptoms in pulmonary arterial hypertension: prevalence and association with functional status. Psychosomatics. 2010;51(4):339-339.e8.
20. Shafazand S, Goldstein MK, Doyle RL, Hlatky MA, Gould MK. Health-related quality of life in patients with pulmonary arterial hypertension. Chest. 2004;126(5):1452-1459. (Pubitemid 39525016)
21. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137(2):376-387.